Puromycin (Synonyms: CL13900)

目录号: HY-B1743 纯度: 99.71%: Data Sheet SDS COA 产品使用指南
FAQs
技术支持

Puromycin 是从细菌链霉菌中分离的氨基糖苷类抗生素。它是一种蛋白质合成抑制剂。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Puromycin Chemical Structure

CAS No. : 53-79-2

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥2292	In-stock
1 mg	￥880	In-stock
5 mg	￥2210	In-stock
10 mg		询价
50 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Other Forms of Puromycin:

MCE 顾客使用本产品发表的 225 篇科研文献

: Puromycin purchased from MCE. Usage Cited in: Autophagy. 2025 Jan 6. [Abstract]; Wild-type or mutated A549 cells subjected to the indicated treatments were stably transfected with puromycin dihydrochloride-inducible stubRFP-sensGFP-LC3 at an MOI of 5 (scale bar: 10 μm).

: Puromycin purchased from MCE. Usage Cited in: Mol Cell. 2023 Nov 24:S1097-2765(23)00911-5. [Abstract]; Global protein synthesis analyzed by puromycin dihydrochloride (4 d) labeling assay upon METTL14 knockdown in HeLa cells. Silencing of EIF3A serves as a positive control.

: Puromycin purchased from MCE. Usage Cited in: Mol Cell. 2023 Nov 24:S1097-2765(23)00911-5. [Abstract]; Global protein synthesis analyzed by puromycin dihydrochloride (4 d) labeling assay upon IGF2BP1-3 knockdown in HeLa cells.

Puromycin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Antibiotic 亚型特异性产品:

查看所有亚型

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

查看 Parasite 亚型特异性产品:

查看所有亚型

Amebae Coccidia Leishmania Mite Plasmodium Toxoplasma Trypanosoma Schistosome

生物活性
纯度 & 产品资料
参考文献

生物活性

Puromycin dihydrochloride is the dihydrochloride salt of puromycin. Puromycin is an aminoglycoside antibiotic that inhibits protein synthesis.

IC₅₀ & Target

Aminoglycoside

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A549	IC₅₀	300 nM Compound: 5	Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs	[PMID: 30418763]
HEK293	CC₅₀	0.23 μM Compound: Puromycin	Cytotoxicity against human HEK293 cells assessed as reduction in cell viability measured after 48 hrs by resazurin assay Cytotoxicity against human HEK293 cells assessed as reduction in cell viability measured after 48 hrs by resazurin assay	[PMID: 33479668]
HEK293	IC₅₀	0.35 nM Compound: Puromycin	Cytotoxicity against HEK293 cells by alamar blue assay Cytotoxicity against HEK293 cells by alamar blue assay	[PMID: 27212070]
HEK293	IC₅₀	0.36 μM Compound: Puromycin	Growth inhibition of HEK293 cells after 72 hrs by PrestoBlue staining based fluorescence assay Growth inhibition of HEK293 cells after 72 hrs by PrestoBlue staining based fluorescence assay	[PMID: 28001067]
HEK293	IC₅₀	0.361 μM Compound: Puromycin	Cytotoxicity against HEK293 cells assessed as cell viability after 72 hrs by resazurin-based plate reader analysis Cytotoxicity against HEK293 cells assessed as cell viability after 72 hrs by resazurin-based plate reader analysis	[PMID: 26651537]
HEK293	IC₅₀	0.4 μM Compound: Puromycin	Cytotoxicity against human HEK293 cells after 72 hrs by resazurin dye based fluorescence assay Cytotoxicity against human HEK293 cells after 72 hrs by resazurin dye based fluorescence assay	[PMID: 29969262]
HEK293	IC₅₀	0.42 μM Compound: Puromycin	Cytotoxicity against HEK239 cells after 72 hrs by Alamar blue assay Cytotoxicity against HEK239 cells after 72 hrs by Alamar blue assay	[PMID: 20558060]
HEK293	IC₅₀	0.45 μM Compound: Puromycin	Cytotoxicity against HEK293 cells after 72 hrs by resazurin dye based assay Cytotoxicity against HEK293 cells after 72 hrs by resazurin dye based assay	[PMID: 29236492]
HEK293	IC₅₀	0.46 μM Compound: Puromycin	Cytotoxicity against HEK293 cells assessed as inhibition of cell growth after 72 hrs by alamar blue assay Cytotoxicity against HEK293 cells assessed as inhibition of cell growth after 72 hrs by alamar blue assay	[PMID: 29533611]
HEK293	IC₅₀	0.46 μM Compound: Puromycin	Cytotoxicity against HEK293 cells assessed as cell growth inhibition after 72 hrs by Alamar blue assay Cytotoxicity against HEK293 cells assessed as cell growth inhibition after 72 hrs by Alamar blue assay	[PMID: 28774427]
HEK293	IC₅₀	0.6645 μM Compound: Puromycin	Cytotoxicity against HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by alamar blue dye based fluorescence assay Cytotoxicity against HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by alamar blue dye based fluorescence assay	[PMID: 36799121]
HEK293	IC₅₀	0.694 μM Compound: Puromycin	Cytotoxicity against HEK293 cells after 72 hrs by resazurin dye-based fluorescence assay Cytotoxicity against HEK293 cells after 72 hrs by resazurin dye-based fluorescence assay	[PMID: 30865443]
HEK293	IC₅₀	0.81 μM Compound: Puromycin	Cytotoxicity against human HEK293 cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay Cytotoxicity against human HEK293 cells assessed as reduction in cell viability after 72 hrs by resazurin dye based assay	[PMID: 33105995]
HEK293	IC₅₀	350.5 nM Compound: Puromycin	Cytotoxicity against HEK293 cells assessed as growth inhibition after 72 hrs by alamar blue viability assay Cytotoxicity against HEK293 cells assessed as growth inhibition after 72 hrs by alamar blue viability assay	[PMID: 27060763]
HEK293	CC₅₀	500.1 nM Compound: Puromycin	Cytotoxicity against HEK293 cells after 72 hrs by resazurin dye based assay Cytotoxicity against HEK293 cells after 72 hrs by resazurin dye based assay	[PMID: 30537832]
HEK-293T	CC₅₀	0.42 μM Compound: Puromycin	Cytotoxicity against human HEK293T cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo reagent based luminescence assay Cytotoxicity against human HEK293T cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo reagent based luminescence assay	[PMID: 29469575]
HepG2	IC₅₀	0.23 μM Compound: puromycin	Growth inhibition of human HepG2 cells after 72 hrs by MTT assay Growth inhibition of human HepG2 cells after 72 hrs by MTT assay	[PMID: 18313307]
HepG2	CC₅₀	0.83 μM Compound: Puromycin	Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo reagent based luminescence assay Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo reagent based luminescence assay	[PMID: 29469575]
HepG2	IC₅₀	2.1 x 10^-1 μM Compound: puromycin	Growth inhibition of human HepG2 cells after 72 hrs by SRB assay Growth inhibition of human HepG2 cells after 72 hrs by SRB assay	[PMID: 18512984]
HepG2	IC₅₀	83.93 μM Compound: puromycin	Growth inhibition of doxorubicin resistant human HepG2 cells after 72 hrs by MTT assay Growth inhibition of doxorubicin resistant human HepG2 cells after 72 hrs by MTT assay	[PMID: 18313307]
HL-60	EC₅₀	0.055 μM Compound: 1	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 28803047]
J774.A1	IC₅₀	10 μM Compound: Puromycin	Cytotoxicity against mouse J774A1 cells by trypan blue exclusion assay Cytotoxicity against mouse J774A1 cells by trypan blue exclusion assay	[PMID: 22934636]
K562	IC₅₀	0.22 μM Compound: puromycin	Growth inhibition of human K562 cells after 72 hrs by SRB assay Growth inhibition of human K562 cells after 72 hrs by SRB assay	[PMID: 18313307]
K562	IC₅₀	26.83 μM Compound: puromycin	Growth inhibition of doxorubicin-resistant human K562 cells after 72 hrs by SRB assay Growth inhibition of doxorubicin-resistant human K562 cells after 72 hrs by SRB assay	[PMID: 18313307]
KB 3-1	IC₅₀	0.21 μM Compound: puromycin	Growth inhibition of human KB3-1 cells after 72 hrs by MTT assay Growth inhibition of human KB3-1 cells after 72 hrs by MTT assay	[PMID: 18313307]
KB-V1	IC₅₀	79.3 μM Compound: puromycin	Growth inhibition of human KB V1 cells after 72 hrs by MTT assay Growth inhibition of human KB V1 cells after 72 hrs by MTT assay	[PMID: 18313307]
MDA-MB-231	CC₅₀	0.48 μM Compound: Puromycin	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by CellTitre-Glo luminescent assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by CellTitre-Glo luminescent assay	[PMID: 28523103]
MIA PaCa-2	CC₅₀	0.2 μM Compound: Puromycin	Cytotoxicity against human MIAPaCa2 cells assessed as growth inhibition after 72 hrs by CellTitre-Glo luminescent assay Cytotoxicity against human MIAPaCa2 cells assessed as growth inhibition after 72 hrs by CellTitre-Glo luminescent assay	[PMID: 28523103]
MOLT-4	EC₅₀	0.17 μM Compound: 1	Antiproliferative activity against human MOLT4 cells after 72 hrs by MTT assay Antiproliferative activity against human MOLT4 cells after 72 hrs by MTT assay	[PMID: 28803047]
PC-3	IC₅₀	300 nM Compound: 5	Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 48 hrs Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 48 hrs	[PMID: 30418763]
SU-DHL10	CC₅₀	0.11 μM Compound: Puromycin	Cytotoxicity against human SU-DHL10 cells assessed as growth inhibition after 72 hrs by CellTitre-Glo luminescent assay Cytotoxicity against human SU-DHL10 cells assessed as growth inhibition after 72 hrs by CellTitre-Glo luminescent assay	[PMID: 28523103]
Vero	CC₅₀	2.8 μM Compound: 1	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell proliferation after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell proliferation after 72 hrs by MTT assay	[PMID: 28803047]

体外研究
(In Vitro)

Puromycin blocks protein synthesis after aminoacyl-sRNA formation, and at the same time it leads to the accumulation of small peptides. Both of these effects appear to be due to the splitting of ribosome-bound peptidyl-sRNA,4 which results in release of incomplete peptide chains.^[1]. Puromycin, an analog of the 3' end of aminoacyl-tRNA, causes premature termination of translation by being linked non-specifically to growing polypeptide chains. Puromycin has two modes of inhibitory action. The first is by acting as an acceptor substrate which attacks peptidyl-tRNA in the P site to form a nascent peptide. The second is by competing with aminoacyl-tRNA for binding to the A' site^[2]. When used in minimal amounts, puromycin incorporation in neosynthesized proteins reflects directly the rate of mRNA translation in vitro. Puromycin immunodetection is an advantageous alternative to radioactive amino acid labeling. It allows the direct evaluation of translation activity in single cells by immunofluorescence microscopy and in heterogenous populations of cells by fluorescenceactivated cell sorting^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

471.51

Formula

C₂₂H₂₉N₇O₅

CAS 号

53-79-2

性状

固体

颜色

White to off-white

中文名称

嘌呤霉素

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

细胞实验：

DMSO 中的溶解度 : 100 mg/mL (212.08 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

H₂O 中的溶解度 : 1 mg/mL (2.12 mM; 超声助溶)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.1208 mL	10.6042 mL	21.2085 mL
5 mM	0.4242 mL	2.1208 mL	4.2417 mL
10 mM	0.2121 mL	1.0604 mL	2.1208 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

* 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (10.60 mM); 澄清溶液

此方案可获得 ≥ 5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (10.60 mM); 澄清溶液

此方案可获得 ≥ 5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 5 mg/mL (10.60 mM); 澄清溶液

此方案可获得 ≥ 5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.71%

选择批次：

Data Sheet (627 KB) SDS (419 KB)

COA (291 KB) HNMR (146 KB) RP-HPLC (168 KB) LCMS (103 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Nathans D, et al. Puromycin inhibition of protein synthesis: incorporation of puromycin intopeptide chains. Proc Natl Acad Sci U S A. 1964 Apr;51:585-92. [Content Brief]

[2]. Miyamoto-Sato E, et al. Specific bonding of puromycin to full-length protein at the C-terminus. Nucleic Acids Res. 2000 Mar 1;28(5):1176-82. [Content Brief]

[3]. Schmidt EK, et al. SUnSET, a nonradioactive method to monitor protein synthesis. Nat Methods. 2009 Apr;6(4):275-7. [Content Brief]

Puromycin 相关分类

Infection

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	2.1208 mL	10.6042 mL	21.2085 mL	53.0211 mL
DMSO	5 mM	0.4242 mL	2.1208 mL	4.2417 mL	10.6042 mL
	10 mM	0.2121 mL	1.0604 mL	2.1208 mL	5.3021 mL
	15 mM	0.1414 mL	0.7069 mL	1.4139 mL	3.5347 mL
	20 mM	0.1060 mL	0.5302 mL	1.0604 mL	2.6511 mL
	25 mM	0.0848 mL	0.4242 mL	0.8483 mL	2.1208 mL
	30 mM	0.0707 mL	0.3535 mL	0.7069 mL	1.7674 mL
	40 mM	0.0530 mL	0.2651 mL	0.5302 mL	1.3255 mL
	50 mM	0.0424 mL	0.2121 mL	0.4242 mL	1.0604 mL
	60 mM	0.0353 mL	0.1767 mL	0.3535 mL	0.8837 mL
	80 mM	0.0265 mL	0.1326 mL	0.2651 mL	0.6628 mL
	100 mM	0.0212 mL	0.1060 mL	0.2121 mL	0.5302 mL

* 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Puromycin53-79-2CL13900嘌呤霉素CL 13900CL-13900BacterialAntibioticParasiteInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Puromycin (Synonyms: CL13900)

Other Forms of Puromycin:

MCE 顾客使用本产品发表的 225 篇科研文献

Puromycin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Antibiotic 亚型特异性产品:

查看 Parasite 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Puromycin 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Puromycin (Synonyms: CL13900)

Other Forms of Puromycin:

Puromycin 相关抗体

MCE 顾客使用本产品发表的 225 篇科研文献

Puromycin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Antibiotic 亚型特异性产品:

查看 Parasite 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

Puromycin 相关抗体:

摩尔计算器

稀释计算器

Puromycin 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z